Clinical experiences with systemically administered siRNA-based therapeutics in cancer.
about
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedsideTargeting SR-BI for Cancer Diagnostics, Imaging and TherapyThe Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice.Liposomal Formulations in Clinical Use: An Updated Review.Molecular dynamics study on the mechanism of polynucleotide encapsulation by chitosanNanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy.Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer-The Case for Combined Delivery?Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system.In silico prediction of novel therapeutic targets using gene-disease association data.Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.Yeast capsules for targeted delivery: the future of nanotherapy?Small Interfering RNA Targeting Mitochondrial Calcium Uniporter Improves Cardiomyocyte Cell Viability in Hypoxia/Reoxygenation Injury by Reducing Calcium Overload.Efficient tuning of siRNA dose response by combining mixed polymer nanocarriers with simple kinetic modeling.Cationic switchable lipids: pH-triggered molecular switch for siRNA delivery.Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.Micro RNAs: an arguable appraisal in medicine.Cancer nanomedicine: progress, challenges and opportunities.Progress in nonviral gene therapy for breast cancer and what comes next?Supramolecular functional assemblies: dynamic membrane transporters and peptide nanotubular composites.Transferrin-Dressed Virus-like Ternary Nanoparticles with Aggregation-Induced Emission for Targeted Delivery and Rapid Cytosolic Release of siRNA.Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.A Simple and Cost-Effective Approach for In Vitro Production of Sliced siRNAs as Potent Triggers for RNAi.Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer.Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathway.Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure.Virus-Mimicking Chimaeric Polymersomes Boost Targeted Cancer siRNA Therapy In Vivo.The long noncoding RNA Tug1 connects metabolic changes with kidney disease in podocytesTargeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment.Esterase-Activated Charge-Reversal Polymer for Fibroblast-Exempt Cancer Gene Therapy.Ki67 targeted strategies for cancer therapy.Anti-inflammatory effects of octadecylamine-functionalized nanodiamond on primary human macrophages.Targeted Delivery of siRNA Therapeutics to Malignant Tumors.Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.
P2860
Q26741449-FD34D6F8-4E97-4AEA-97E3-0D840BBCDE0AQ28066708-1DEE947D-FDC5-45F6-B56D-AE2E092E9131Q33624987-57C5561D-A86C-4AB1-ABAD-0A4BDC794435Q33850427-4A671DD6-0FEB-4777-A9D5-B452AE6A38A8Q33895017-AFD6CA84-0E22-43F5-A8E1-DA995AA3ECAEQ34537580-3B13176B-756A-4F09-8BF4-A6C3DFEC2F8EQ36291372-0FD2BAD3-CC3E-48EE-9D5E-05733FBC1CCAQ36382827-F881691A-DA0A-4D5C-9AA3-94AFE3D19121Q36784555-A088745B-0037-4EAB-8257-629BECEDFDDAQ37102453-8CDB7498-9623-45B8-831B-19324126423FQ37641686-8D04A288-63FB-4E82-923A-922145551A83Q37724113-F87BC904-DD06-496D-954E-04D54EEADCCFQ37735811-131C462A-DA77-420D-AAA5-5A6D4E331B2DQ38603369-12F61CCB-4B12-419D-ADCA-4D4AB562A6AAQ38674708-465C61B2-D01B-45AB-A84E-637773E29512Q38691189-B9EA2C9A-23A3-4021-AC8D-919697C29D29Q38710888-6E242B94-48EC-4CA5-9377-47260EC3EE60Q38773494-12832C38-EB48-42FF-A895-ED6AD7B4B6E8Q38788622-3C2EDC43-3C2F-496E-84E9-51B9ACC83E48Q38871344-479D5313-66A8-402B-B290-CCE8CE4AFB67Q38889573-AB7F63FA-D12D-43E3-B54A-958C06E513DFQ38934039-FA84452C-ACAA-45C6-9E31-50477A2EE11EQ38937055-FD8147F3-1B90-4C6A-8ED5-43F86F8465A5Q39005226-11088AB5-FF25-47D6-BEB9-8122FC20C097Q39194052-A8E3CA4E-6C79-449D-801A-B167C9D54F17Q39387945-2963AC60-B846-44E6-A9BC-E39F439E7329Q40225850-5BC69E3B-DFF0-4901-8A36-DBE3E03DD69DQ41139938-5CA57BE4-FD6A-43C9-9E2A-677F42B3B661Q41191245-DDB7FEDE-39AD-4A7D-BBFA-623651342BD7Q41514193-15A02223-307F-409C-A02A-3C0A8C691F47Q41613353-3DEB9909-443E-4DBC-8198-DC2240F2276EQ41728608-1F0F88D8-4679-4CEB-B0B4-AA8130B8ECA7Q41928019-0AE77BCE-930D-4438-B6A5-F800E2C5C015Q42734485-B047D97C-3B48-48C3-A429-2A48E15ED747Q45363189-3B826943-DB0D-4977-9BCA-224F62B6A8C2Q45861301-D02ABE3A-6085-4E59-8078-466B38256E8CQ45873470-8EBC7580-6FEA-4117-98DA-D76EC099DAAEQ47145944-231AC6D1-BF98-48CD-8F1E-E0252D646CEBQ47152520-4152019F-7422-45E3-ADD1-464E565EB92FQ47217912-2498E411-D675-43B7-A04F-227CC9E95335
P2860
Clinical experiences with systemically administered siRNA-based therapeutics in cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical experiences with systemically administered siRNA-based therapeutics in cancer.
@en
type
label
Clinical experiences with systemically administered siRNA-based therapeutics in cancer.
@en
prefLabel
Clinical experiences with systemically administered siRNA-based therapeutics in cancer.
@en
P356
P1476
Clinical experiences with systemically administered siRNA-based therapeutics in cancer.
@en
P2093
Jonathan E Zuckerman
Mark E Davis
P2888
P304
P356
10.1038/NRD4685
P577
2015-11-16T00:00:00Z